As of February 15, 2024, the analyst ratings for CME Group (NASDAQ:CME) have shown a mix of opinions over the past three months, with a noticeable shift towards a more cautious stance in the last 30 days. Here is a summary of the evolution of analyst sentiments:
– Total Ratings: 0 Bullish, 0 Somewhat Bullish, 2 Indifferent, 0 Somewhat Bearish, 2 Bearish
– Last 30 Days: 0 Bullish, 0 Somewhat Bullish, 1 Indifferent, 0 Somewhat Bearish, 0 Bearish
– 1 Month Ago: 0 Bullish, 0 Somewhat Bullish, 0 Indifferent, 0 Somewhat Bearish, 0 Bearish
– 2 Months Ago: 0 Bullish, 0 Somewhat Bullish, 1 Indifferent, 0 Somewhat Bearish, 2 Bearish
– 3 Months Ago: 0 Bullish, 0 Somewhat Bullish, 0 Indifferent, 0 Somewhat Bearish, 0 Bearish
Analysts have set a 12-month price target for CME Group, with an average target of $205.5. The high estimate is $225.00, while the low estimate is $180.00. This represents an 11.8% decrease from the previous average price target of $233.00.
Recent analyst actions include:
– Benjamin Budish of Barclays raised the rating to Equal-Weight with a price target of $225.00, up from $222.00, but previously lowered it from $244.00 to $222.00.
– Andrew Bond of Rosenblatt maintains a Sell rating with a price target of $180.00.
– Alexander Blostein of Goldman Sachs announced a Sell rating with a price target of $195.00.
These adjustments reflect analysts’ responses to changing market conditions and the performance of the company. The ratings range from “Maintain” to “Raise” or “Lower,” indicating varying degrees of optimism or caution regarding CME Group’s future performance.
CME Group Inc. (CME) Stock Performance Declines by 1.98% on February 15, 2024: CNN Money Report
On February 15, 2024, CME Group Inc. (CME) experienced a decline in its stock performance, as reported by CNN Money. The trading price of CME shares dropped by $4.26, representing a decrease of 1.98% since the previous market close.
CME Group Reports Strong Financial Performance with Double-Digit Revenue and Net Income Growth
CME Group reported its stock performances on February 15, 2024. According to data sourced from CNN Money, CME Group’s total revenue for the past year stood at $5.58 billion, marking an 11.15% increase compared to the previous year. The company’s net income for the past year was reported at $3.19 billion, reflecting an 18.16% increase since the previous year. Earnings per share (EPS) for CME Group exhibited positive growth, with an increase of 19.76% since the previous year, reaching $8.86. These financial indicators suggest that CME Group has experienced solid growth in both revenue and net income over the past year. CME Group’s strong performance can be attributed to several factors, including increased trading volumes, higher transaction fees, diverse product offerings, and strategic investments in technology. Looking ahead, CME Group is well-positioned to continue its growth trajectory.
